Unassociated Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
January 12, 2009
Date of Report (Date of earliest event reported)

KIWA BIO-TECH PRODUCTS GROUP CORPORATION
(Exact name of registrant as specified in its charter)

Delaware
  
000-33167
  
77-0632186
(State or other jurisdiction of incorporation)
  
(Commission File Number)
  
(IRS Employer Identification No.)
         
   
310 N. Indian Hill Blvd., #702
Claremont, California
    
   
(Address of principal executive offices)
    
         
   
91711
    
   
(Zip code)
    
         
   
(626) 715-5855
    
   
(Registrant’s telephone number, including area code)
    
         
   
None.
    
   
(Former name or former address, if changed since last report)
    

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions.
 
 
o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 
   
o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 
   
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 
         

 
 
 
 
Item 5.02 Departure Principal Officer;

On January 12, 2009, Mr. Xiaonan Wu, resigned as the Vice President of Kiwa Bio-Tech Products Group Corporation (the “Company”) and our Board of Directors approved his resignation on the same day.  Mr. Wu’s resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.




SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 12, 2009         
         
         
 
By:      /s/ Wei Li      
 
Name: Wei Li
    
 
  
Title: Chairman of Board of Directors and Chief Executive Officer